130 related articles for article (PubMed ID: 27384995)
1. Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells.
Shi Y; Huang XX; Chen GB; Wang Y; Zhi Q; Liu YS; Wu XL; Wang LF; Yang B; Xiao CX; Xing HQ; Ren JL; Xia Y; Guleng B
Oncotarget; 2016 Jul; 7(30):48027-48037. PubMed ID: 27384995
[TBL] [Abstract][Full Text] [Related]
2. Dragon (repulsive guidance molecule b, RGMb) is a novel gene that promotes colorectal cancer growth.
Shi Y; Chen GB; Huang XX; Xiao CX; Wang HH; Li YS; Zhang JF; Li S; Xia Y; Ren JL; Guleng B
Oncotarget; 2015 Aug; 6(24):20540-54. PubMed ID: 26029998
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
[TBL] [Abstract][Full Text] [Related]
4. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
5. Dragon (repulsive guidance molecule RGMb) inhibits E-cadherin expression and induces apoptosis in renal tubular epithelial cells.
Liu W; Li X; Zhao Y; Meng XM; Wan C; Yang B; Lan HY; Lin HY; Xia Y
J Biol Chem; 2013 Nov; 288(44):31528-39. PubMed ID: 24052264
[TBL] [Abstract][Full Text] [Related]
6. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
7. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells.
Shiragami R; Murata S; Kosugi C; Tezuka T; Yamazaki M; Hirano A; Yoshimura Y; Suzuki M; Shuto K; Koda K
Int J Oncol; 2013 Aug; 43(2):431-8. PubMed ID: 23754252
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
[TBL] [Abstract][Full Text] [Related]
10. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
12. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
13. γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells.
Song L; Du A; Xiong Y; Jiang J; Zhang Y; Tian Z; Yan H
Tumour Biol; 2016 Nov; 37(11):14885-14894. PubMed ID: 27644246
[TBL] [Abstract][Full Text] [Related]
14. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.
Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X
Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807
[TBL] [Abstract][Full Text] [Related]
15. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
[TBL] [Abstract][Full Text] [Related]
18. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
19. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
[TBL] [Abstract][Full Text] [Related]
20. MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.
Peng L; Zhu H; Wang J; Sui H; Zhang H; Jin C; Li L; Xu T; Miao R
Mol Cell Biochem; 2015 Jul; 405(1-2):73-9. PubMed ID: 25862460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
